Switzerland-based GeNeuro SA has raised €17.5 million in a private share placement, enabling it to complete a new clinical trial of its experimental treatment for multiple sclerosis temelimab. The trial will be conducted at the Karolinska Institutet and the Academic Specialist Center in Stockholm, Sweden and is expected to report results in the second half of 2021.
